Adaptive Pharmacogenomics, LLC

Clinical development for personalized medicine

Sunday, September 5, 2010 | 1:28 AM

Archive

Molecular markers in the treatment of metastatic colorectal cancer.

Cancer J. 2010 May-Jun;16(3):262-72

Authors: Wilson PM, Labonte MJ, Lenz HJ

Although significant progress has been made in colorectal cancer (CRC) treatment within the last decade with the approval of multiple new agents, the prognosis for patients with metastatic CRC remains poor with 5-year survival rates of approximately 8%.

Sep 04, 2010 03:23 AM

Emerald BioStructures and SomaLogic Enter Strategic Collaboration

Emerald BioStructures, a leading provider of integrated structural biology services, and SomaLogic, Inc., a diagnostics and biomarker discovery company, today announced that they have entered into a strategic collaboration for the structure-based des...
Sep 03, 2010 09:00 AM

Wanted: An Early Biomarker for Acute Kidney Injury

Is there a biomarker or combination of biomarkers that provides an earlier indication of AKI than serum creatinine? Dr. Jeff Berns reports on a cursory review of 3000 publications.
Medscape Nephrology
Sep 02, 2010 12:25 PM

Genetic diversity and medicinal drug response in eye care.

Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1057-61

Authors: Shastry BS

BACKGROUND: Individual variation in drug response and adverse drug reactions are a serious problem in medicine. This inter-individual variation in drug response could be due to multiple factors such as disease determinants, environmental and genetic factors.

Sep 01, 2010 03:23 AM

Personalized medicine: Molecular imaging predicts treatment success in many cancers

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.
Sep 01, 2010 12:00 AM

Functional hot spots in human ABC transporter nucleotide binding domains.

Protein Sci. 2010 Aug 26;

Authors: Kelly L, Fukushima H, Karchin R, Gow JM, Chinn LW, Pieper U, Segal MR, Kroetz DL, Sali A

The human ATP-binding cassette (ABC) transporter superfamily consists of 48 integral membrane proteins that couple the action of ATP binding and hydrolysis to the transport of diverse substrates across cellular membranes.

Aug 29, 2010 03:23 AM

Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.

Psychiatr Danub. 2010 Jun;22(2):335-7

Authors: MihaljeviÄ-Peles A, Sagud M, Bozina N, ZivkoviÄ M, JovanoviÄ N

The concept of personalized drug therapy on the basis of genetic investigations has become a major issue in psychopharmacology. Pharmacogenetic studies have focused on polymorphisms in liver cytochrome P450 isoenzymes that metabolize many antidepressant and antipsychotic medications.

Aug 29, 2010 03:23 AM

[Development of heart failure in the course of coronary artery disease--the role of genetic factors]

Kardiol Pol. 2005 Oct;63(4 Suppl 2):S440-9

Authors: Kozieradzka A, KamiÅski K, MusiaÅ WJ

The number of patients suffering from heart failure is constantly increasing. One of its main causes is coronary artery disease, especially myocardial infarction. Progression of heart failure depends both on the extent of ischaemic injury and the course of subsequent adaptive processes.

Aug 28, 2010 03:23 AM

Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Future Oncol. 2010 Apr;6(4):563-85

Authors: Ramírez J, Ratain MJ, Innocenti F

Pharmacogenetics aims to elucidate how genetic variation affects the efficacy and side effects of drugs, with the ultimate goal of personalizing medicine.

Aug 26, 2010 03:23 AM

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.

Pharmacogenomics J. 2010 Jun;10(3):191-9

Authors: Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD

The anticancer agent docetaxel shows significant inter-individual variation in its pharmacokinetic and toxicity profile. Thalidomide is an active anticancer agent and also shows wide pharmacological variation.

Aug 25, 2010 03:23 AM
© 2008 — 2010 Adaptive Pharmacogenomics, LLC